Thursday, Aug 25, 1994
South San Francisco, Calif. -- August 25, 1994 --Genentech, Inc. (NYSE: GNE) today announced the promotions Dennis Henner and Bryan Lawlis to vice president.
Henner, who joined Genentech in 1981, was named Vice President, Research Technology. Henner is responsible for managing five research technology departments-Molecular Biology, Cell Genetics, Bioorganic Chemistry, Protein Chemistry and Protein Engineering. He is also a member of the Research Review Committee, a group dedicated to setting strategies for all of research. Henner's most recent position was Staff Scientist and Senior Director, Research Technology. Henner joined the company as a scientist in Research.
Prior to his employment with Genentech, Henner was at Scripps Clinic and Research Foundation. He holds a doctorate in Microbiology from the University of Virginia Medical School.
Lawlis, who also joined Genentech in 1981, was named Vice President, Process Sciences. Lawlis is responsible for the process sciences group, which comprises 170 scientists and designs and develops all processes Genentech uses to produce pharmaceuticals for clinical trials and for the market. The process sciences group includes the Cell Culture and Fermenation R&D, Product Recovery R&D and Pharmaceutical R&D departments. His most recent position was Senior Director, Process Sciences. Lawlis joined the company as a scientist in Biocatalysis.
Prior to joining Genentech, Lawlis was a National Institutes of Health Post Doctoral Fellow at Kansas State University. Lawlis holds a bachelor's of arts degree in Microbiology from the University of Texas and a doctorate in Biochemistry from Washington State University.
Genentech, Inc. is a leading international biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.
# # #